Clinical & Scientific

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

Laurie Ann Goldman, the branding guru who built SPANX, is now CEO of Audien Hearing. Can she make affordable hearing aids a mainstream wellness product?

Kincell Bio and RegCell partner to bring a groundbreaking, non-gene-edited Treg cell therapy for autoimmune diseases from the lab to clinical trials.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

A new German partnership aims to create variant-ready, room-temperature stable vaccines, moving beyond the limits of first-generation mRNA technology.

Ernexa Therapeutics secures crucial funding for its cancer therapy pipeline, but the dilutive offering sends its stock plunging more than 50%.

After clearing the EU's rigorous MDR hurdle, P&F's novel heart valve system secures its European future and sets its sights on the lucrative US market.

A new partnership aims to overcome the hurdles of at-home testing by combining instrument-free PCR with advanced enzymes for rapid, reliable results.

CoSara Diagnostics' ISO 13485 certification paves the way for regulatory approval of a new PCR platform, leveraging India's 'Make in India' initiative.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

With a key cancer drug awaiting FDA review and pivotal data imminent, Celcuity faces investors at a critical juncture. What will they be looking for?

A new class of compounds 'disarms' TB bacteria instead of killing it, a breakthrough that could help defeat drug resistance and treat the world's deadliest disease.

A major multi-vendor study confirms AI's power for precision HER2 scoring, promising to improve diagnostics and accelerate personalized cancer therapies.

With an extra $3M, Aduro Clean Technologies advances its game-changing plant, turning investor confidence into a reality for recycling and energy.

With a major cash infusion, NeOnc Technologies is set to accelerate its promising therapies aimed at conquering the elusive blood-brain barrier.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

Top scientists, survivors, and industry leaders are uniting to accelerate a new generation of cancer vaccines, moving them from lab to patient faster than ever.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.